Holen Sie sich die Stockscreener-App
1.70
1.16%
-0.02
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Dare Bioscience (DARE) Launches Telehealth for Topical Sildenafi - GuruFocus
Telehealth Now Available for DARE to PLAY™ Sildenafil - GlobeNewswire
Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion - AD HOC NEWS
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com
Daré Bioscience Launches Regulation A Preferred Unit Offering - TipRanks
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Yahoo Finance
Dare Bioscience (NASDAQ:DARE) Share Price Passes Below 50-Day Moving Average – What’s Next? - Defense World
Daré Bioscience issues updated investor corporate presentation - MSN
Daré Bioscience Issues Updated Investor Corporate Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience Earnings Notes - Trefis
Is Dare Bioscience Inc (DARE) a opportunity to investors? - uspostnews.com
Viagra for women rolling out in select states - NewsNation
A History of Outperforming Analyst Forecasts and Beating the Odds: Dare Bioscience Inc (DARE) - setenews.com
‘Viagra’ for women hits the shelves – 30 years after men got little blue pills - AOL.com
Sildenafil cream for female sexual arousal disorder available to prescribe in select states - Urology Times
DARE to PLAY sildenafil cream becomes commercially available for women in select states - Contemporary OB/GYN
Dare Bioscience (DARE) Launches Prescription for Women's Topical Arousal Cream - GuruFocus
Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative
Daré Bioscience (NASDAQ: DARE) starts 503B DARE to PLAY cream access in select states - Stock Titan
Viagra goes pink (finally!): First-of-its-kind cream promises to jump-start arousal in women - New York Post
Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada
DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Canada
Dare Bioscience (DARE) Regains Ovaprene Rights from Bayer - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer - Investing.com
Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data - marketscreener.com
Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data - TradingView — Track All Markets
Daré Bioscience (NASDAQ: DARE) regains Ovaprene rights after Phase 3 interim data - Stock Titan
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - Sahm
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
[1-A] Dare Bioscience, Inc. SEC Filing - Stock Titan
Daré Bioscience receives $3.6 million grant payment for contraceptive work By Investing.com - Investing.com Nigeria
DARE Secures Additional $3.6 Million from Gates Foundation - GuruFocus
Daré Bioscience Receives $3.6 Million in Additional Grant Funding - The Manila Times
Daré Bioscience receives $3.6 million grant payment for contraceptive work - Investing.com
Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next? - Defense World
Dare Bioscience Inc. (DARE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Str - GuruFocus
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience (DARE) Q3 2025 Earnings Transcript - AOL.com
Transcript : Daré Bioscience, Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Dare Bioscience Q3 2025 sees mixed stock reaction - Investing.com Nigeria
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
DARE Bioscience Prepares for Launch of Sildenafil Cream - GuruFocus
Daré Bioscience Q3 2025 Financial Results and Corporate Update - TradingView
Daré (NASDAQ: DARE) to launch DARE to PLAY Sildenafil Cream in December via 503B pathway - Stock Titan
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):